{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:12:34Z","timestamp":1793041954639,"version":"4.5.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T00:00:00Z","timestamp":1647820800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T00:00:00Z","timestamp":1647820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This pilot prospective study investigated the effect of a periodic fasting mimicking diet (FMD) on metabolic health factors in patients with Prostate Cancer (PC). There is a well-documented association between PC and metabolic health. Impaired metabolic health is a significant risk factor for the development of PC, and a metabolic syndrome can be induced by hormonal therapies commonly required for its management. (ClinicalTrials.gov Identifier: NCT04292041).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We introduced a periodic 4-day FMD -low in calories, sugars, and proteins but high in unsaturated fats -to a cohort of PC patients and features of metabolic syndrome. 29\/35 patients completed 3-monthly cycles of the 4-consecutive day packaged FMD. We compared the subjects\u2019 baseline weight, abdominal circumference (AC), blood pressure (BP) and selected laboratory results to the same measurements 3-months after completing the FMD cycles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Several important metabolic factors showed improvements post-intervention. On average patients\u2019 weights dropped by 3.79\u2009kg (95% CI: \u22125.61, \u22121.97,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0002). AC was reduced on average by 4.57\u2009cm, (95% CI: \u22122.27, \u22126.87,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0003). There was also a decrease in systolic and diastolic BP by 9.52\u2009mmHg (95% CI: \u221216.16, \u22122.88,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0066) and 4.48\u2009mmHg (95% CI: \u22128.85, \u22120.43,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0316) respectively. A sub-analysis indicates that FMD had more relevant effects in \u2018at-risk\u2019 patients than those with normal values of risk factors for metabolic syndrome. For example, subjects with baseline levels of systolic BP\u2009&gt;\u2009130\u2009mmHg experienced a greater reduction in BP(\u221216.04\u2009mmHg,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0001) than those with baseline systolic BP\u2009&lt;\u2009130\u2009mmHg (\u22120.78\u2009mmHg,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.89).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The FMD cycles were safely introduced to this small cohort of PC patients with little or no observed toxicity, and a high overall compliance of 83%. Analysis of the metabolic variables showed an overall decrease in weight, AC, and BP. Larger clinical trials focused on metabolic risk factors, PC quality of life and progression free survival are needed to assess the effect of the FMD on prostate cancer patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41391-022-00528-3","type":"journal-article","created":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T14:05:06Z","timestamp":1647871506000},"page":"317-322","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["The impact of a fasting mimicking diet on the metabolic health of a prospective cohort of patients with prostate cancer: a pilot implementation study"],"prefix":"10.1038","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3863-0177","authenticated-orcid":false,"given":"V.","family":"Fay-Watt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"O\u2019Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Roshan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. C.","family":"Romeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V. D.","family":"Longo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5111-5383","authenticated-orcid":false,"given":"F. J.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,21]]},"reference":[{"key":"528_CR1","doi-asserted-by":"publisher","first-page":"9575","DOI":"10.7314\/APJCP.2014.15.22.9575","volume":"15","author":"M Daniyal","year":"2014","unstructured":"Daniyal M, Siddiqui ZA, Akram M, Asif HM, Sultana S, Khan A. Epidemiology, etiology, diagnosis and treatment of prostate cancer. Asian Pac J Cancer Prev. 2014;15:9575\u20138.","journal-title":"Asian Pac J Cancer Prev."},{"key":"528_CR2","doi-asserted-by":"publisher","first-page":"802","DOI":"10.3332\/ecancer.2018.802","volume":"12","author":"D Crawley","year":"2018","unstructured":"Crawley D, Chamberlain F, Garmo H, Rudman S, Zethelius B, Holmberg L, et al. A systematic review of the literature exploring the interplay between prostate cancer and type two diabetes mellitus. Ecancermedicalscience. 2018;12:802.","journal-title":"Ecancermedicalscience."},{"key":"528_CR3","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1001\/jamaoncol.2015.2895","volume":"1","author":"S Magnan","year":"2015","unstructured":"Magnan S, Zarychanski R, Pilote L, Bernier L, Shemilt M, Vigneault E, et al. Intermittent vs continuous androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. JAMA Oncol. 2015;1:1261\u20139.","journal-title":"JAMA Oncol."},{"key":"528_CR4","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1056\/NEJMcibr1800808","volume":"378","author":"C Abate-Shen","year":"2018","unstructured":"Abate-Shen C. Prostate cancer metastasis - fueled by fat? N Engl J Med. 2018;378:1643. -","journal-title":"N Engl J Med."},{"key":"528_CR5","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1200\/JCO.20.00791","volume":"38","author":"CH Marshall","year":"2020","unstructured":"Marshall CH, Joshu CE. Mounting weight of evidence on the importance of body weight for men with prostate cancer. J Clin Oncol. 2020;38:2007\u20139.","journal-title":"J Clin Oncol."},{"key":"528_CR6","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1200\/JCO.19.02185","volume":"38","author":"AN Troeschel","year":"2020","unstructured":"Troeschel AN, Hartman TJ, Jacobs EJ, Stevens VL, Gansler T, Flanders WD, et al. Postdiagnosis body mass index, weight change, and mortality from prostate cancer, cardiovascular disease, and all causes among survivors of nonmetastatic prostate cancer. J Clin Oncol. 2020;38:2018\u201327.","journal-title":"J Clin Oncol."},{"key":"528_CR7","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.cct.2019.04.004","volume":"81","author":"JM Schenk","year":"2019","unstructured":"Schenk JM, Neuhouser ML, Beatty SJ, VanDoren M, Lin DW, Porter M, et al. Randomized trial evaluating the role of weight loss in overweight and obese men with early stage prostate Cancer on active surveillance: Rationale and design of the Prostate Cancer Active Lifestyle Study (PALS). Contemp Clin Trials. 2019;81:34\u20139.","journal-title":"Contemp Clin Trials."},{"key":"528_CR8","doi-asserted-by":"publisher","first-page":"124ra27","DOI":"10.1126\/scitranslmed.3003293","volume":"4","author":"C Lee","year":"2012","unstructured":"Lee C, Raffaghello L, Brandhorst S, Safdie FM, Bianchi G, Martin-Montalvo A, et al. Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy. Sci Transl Med. 2012;4:124ra27.","journal-title":"Sci Transl Med."},{"key":"528_CR9","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s43587-020-00013-3","volume":"1","author":"VD Longo","year":"2021","unstructured":"Longo VD, Di Tano M, Mattson MP, Guidi N. Intermittent and periodic fasting, longevity and disease. Nat Aging. 2021;1:47\u201359.","journal-title":"Nat Aging"},{"key":"528_CR10","doi-asserted-by":"crossref","unstructured":"Wei M, Brandhorst S, Shelehchi M, Mirzaei H, Cheng CW, Budniak J, et al. Fasting-mimicking diet and markers\/risk factors for aging, diabetes, cancer, and cardiovascular disease. Sci Transl Med. 2017;9:eaai8700.","DOI":"10.1126\/scitranslmed.aai8700"},{"key":"528_CR11","doi-asserted-by":"publisher","first-page":"34485","DOI":"10.18632\/oncotarget.26128","volume":"9","author":"C Lavalette","year":"2018","unstructured":"Lavalette C, Tretarre B, Rebillard X, Lamy PJ, Cenee S, Menegaux F. Abdominal obesity and prostate cancer risk: epidemiological evidence from the EPICAP study. Oncotarget. 2018;9:34485\u201394.","journal-title":"Oncotarget."},{"key":"528_CR12","doi-asserted-by":"publisher","first-page":"6199","DOI":"10.1002\/cncr.27677","volume":"118","author":"C Haggstrom","year":"2012","unstructured":"Haggstrom C, Stocks T, Ulmert D, Bjorge T, Ulmer H, Hallmans G, et al. Prospective study on metabolic factors and risk of prostate cancer. Cancer. 2012;118:6199\u2013206.","journal-title":"Cancer."},{"key":"528_CR13","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1097\/COC.0b013e318201a406","volume":"35","author":"A Collier","year":"2012","unstructured":"Collier A, Ghosh S, McGlynn B, Hollins G. Prostate cancer, androgen deprivation therapy, obesity, the metabolic syndrome, type 2 diabetes, and cardiovascular disease: a review. Am J Clin Oncol. 2012;35:504\u20139.","journal-title":"Am J Clin Oncol."},{"key":"528_CR14","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.eururo.2014.07.010","volume":"67","author":"PL Nguyen","year":"2015","unstructured":"Nguyen PL, Alibhai SM, Basaria S, D\u2019Amico AV, Kantoff PW, Keating NL, et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol. 2015;67:825\u201336.","journal-title":"Eur Urol."},{"key":"528_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-021-01935-x","volume":"16","author":"JO Kim","year":"2021","unstructured":"Kim JO, McDonald MO, Ong A, Koul R, Dubey A, Hunter W, et al. Gastrointestinal and genitourinary toxicity profiles of metformin versus placebo in men with prostate cancer receiving prostate radiotherapy: interim toxicity results of a double-blinded, multicenter, phase II randomized controlled trial. Radiat Oncol. 2021;16:212.","journal-title":"Radiat Oncol."},{"key":"528_CR16","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.cmet.2015.05.012","volume":"22","author":"S Brandhorst","year":"2015","unstructured":"Brandhorst S, Choi IY, Wei M, Cheng CW, Sedrakyan S, Navarrete G, et al. A periodic diet that mimics fasting promotes multi-system regeneration, enhanced cognitive performance, and healthspan. Cell Metab. 2015;22:86\u201399.","journal-title":"Cell Metab."},{"key":"528_CR17","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1017\/S0007114513000792","volume":"110","author":"M Harvie","year":"2013","unstructured":"Harvie M, Wright C, Pegington M, McMullan D, Mitchell E, Martin B, et al. The effect of intermittent energy and carbohydrate restriction v. daily energy restriction on weight loss and metabolic disease risk markers in overweight women. Br J Nutr. 2013;110:1534\u201347.","journal-title":"Br J Nutr."}],"updated-by":[{"DOI":"10.1038\/s41391-022-00540-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T00:00:00Z","timestamp":1652832000000}}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-022-00528-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-022-00528-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-022-00528-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T09:04:47Z","timestamp":1686128687000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-022-00528-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,21]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["528"],"URL":"https:\/\/doi.org\/10.1038\/s41391-022-00528-3","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,21]]},"assertion":[{"value":"16 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2022","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41391-022-00540-7","URL":"https:\/\/doi.org\/10.1038\/s41391-022-00540-7","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"VDL, has equity interest in L-Nutra, a company producing medical food. Other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}